Of these two groups, initially planned sRT was modified in 33 patients by giving stereotactic ablative RT (SABR) to extraprostatic OMD, while in five patients, the treatment shifted to ADT due to multimetastatic disease detection on PSMA-PET/CT. This evidence concerns the gene FOLH1 and occult macular dystrophy.